ArticleACS infectious diseases2015
Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and "Anagrams" Generated Potent Antituberculosis Agents.
Article in ACS infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Imidazo[1,2‑ACS omega · 2026Review
- Recent developments of imidazo[1,2-RSC medicinal chemistry · 2023Review
- Syntheses and studies of deuterated Imdiazo[1,2-a]pyridine-3-carboxamides with potent anti-tuberculosis activity and improved metabolic properties.Bioorganic chemistry · 2022Article
- Targeting the cytochrome bcMolecular diversity · 2022Review
- Prediction of QcrB Inhibition as a Measure of Antitubercular Activity with Machine Learning Protocols.ACS omega · 2022Article
- Synthetic approaches to potent heterocyclic inhibitors of tuberculosis: A decade review.Frontiers in pharmacology · 2022Review
- Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition ofRSC advances · 2021Article
- Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridinecarboxamides as potent anti-tuberculosis agents.Chemical biology & drug design · 2020Article
- SAR Analysis of Small Molecules Interfering with Energy-Metabolism inPharmaceuticals (Basel, Switzerland) · 2020Review
- Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.PloS one · 2020Article
- Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?Frontiers in cellular and infection microbiology · 2020Review
- Identification of 4-Amino-Thieno[2,3-mSphere · 2019Article
- Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.Antimicrobial agents and chemotherapy · 2018Article
- Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance.The Journal of membrane biology · 2018Article
- Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds.ChemMedChem · 2017Article
- SAR and identification of 2-(quinolin-4-yloxy)acetamides asMedChemComm · 2016Article
- Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo.Antimicrobial agents and chemotherapy · 2016Article
- New agents for the treatment of drug-resistant Mycobacterium tuberculosis.Advanced drug delivery reviews · 2016Review
- Endless Resistance. Endless Antibiotics?MedChemComm · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Zolpidem (Ambien,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.